<div id="readability-page-1"><p>AKO Capital LLP grew its position in  Zoetis Inc. (NYSE:ZTS - Free Report) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor  owned 1,505,938 shares of the company's stock after buying an additional 13,800 shares during the quarter. Zoetis accounts for approximately  3.4% of AKO Capital LLP's holdings, making the stock its 17th biggest holding. AKO Capital LLP owned 0.33% of Zoetis worth $245,362,000 at the end of the most recent quarter.</p><ul><li>Which Pet Stock Should Get Your Tail Wagging in 2024?</li></ul><p>Several other hedge funds and other institutional investors have also made changes to their positions in ZTS. Norges Bank purchased a new position in  Zoetis during the 4th quarter valued at about $824,321,000.  Raymond James Financial Inc. acquired a new position in shares of  Zoetis during the 4th quarter worth approximately $196,651,000.  Polen Capital Management LLC lifted its stake in  Zoetis by 17.5% in the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company's stock valued at $1,219,237,000 after buying an additional 1,116,541 shares in the last quarter.  Amundi grew its holdings in  Zoetis by 46.2% during the 4th quarter. Amundi now owns 2,748,719 shares of the company's stock valued at $453,355,000 after buying an additional 867,993 shares during the last quarter.  Finally, Assenagon Asset Management S.A. increased its position in  Zoetis by 296.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company's stock worth $144,917,000 after buying an additional 665,331 shares in the last quarter. Institutional investors and hedge funds own  92.80% of the company's stock. </p><h2>Zoetis Price Performance</h2><p>Shares of Zoetis stock opened at $162.56 on Thursday. The business's fifty day moving average price is $166.55 and its 200 day moving average price is $174.94. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $72.79 billion, a P/E ratio of 29.72, a PEG ratio of 2.78 and a beta of 0.94. </p><ul><li>MarketBeat Week in Review – 07/31 - 08/04</li></ul><p>Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%.  As a group, research analysts anticipate that  Zoetis Inc. will post 6.07 earnings per share for the current year. </p><h2>Zoetis Dividend Announcement</h2><p>The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.23%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's payout ratio is 36.56%. </p><h2>Insiders Place Their Bets</h2><ul><li>Rising Dividend Make Zoetis a Doggone Winner</li></ul><p>In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,862 shares of company stock worth $312,254. Insiders own  0.16% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of research firms recently commented on ZTS. Barclays increased their price objective on Zoetis from $242.00 to $244.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, February 14th. StockNews.com raised shares of Zoetis from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Friday, March 7th. Piper Sandler boosted their price objective on shares of Zoetis from $200.00 to $205.00 and gave the company an &#34;overweight&#34; rating in a research report on Thursday, February 27th. Leerink Partnrs upgraded shares of Zoetis to a &#34;strong-buy&#34; rating in a research report on Monday, December 2nd. Finally, Stifel Nicolaus cut their price target on Zoetis from $210.00 to $180.00 and set a &#34;buy&#34; rating for the company in a report on Tuesday, January 7th. One equities research analyst  has rated the stock with a hold rating, ten have given a buy rating and two have issued  a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of &#34;Buy&#34; and a consensus price target of $215.90.</p><p><b>Get Our Latest Research Report on Zoetis</b></p><h2>About Zoetis</h2> (Free Report)<p>Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Zoetis</li><li>What Are Earnings Reports?</li><li>Maybe It’s Time to Buy Some GameStop Stock</li><li>How to Invest in Tech Stocks and Top Tech Stocks to Consider</li><li>Price Targets Show These 3 Stocks Near the $1 Trillion Mark</li><li>How to Calculate Retirement Income: MarketBeat’s Calculator</li><li>Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead</li></ul><p><strong>Want to see what other hedge funds are holding ZTS?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpUUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVpUUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Zoetis Right Now?</h2><p>Before you consider Zoetis, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.</p><p>While Zoetis currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>AKO Capital LLP increased its stake in Zoetis Inc. (NYSE:ZTS) by 0.9% in Q4, owning 1,505,938 shares after acquiring 13,800 additional shares. Zoetis represents 3.4% of AKO's portfolio. Other institutional investors also adjusted their positions, with Norges Bank investing $824 million and Polen Capital increasing its stake by 17.5%. Zoetis shares opened at $162.56, with a market cap of $72.79 billion and a P/E ratio of 29.72. The company announced a quarterly dividend of $0.50 per share, payable on June 3rd.</p>

AKO Capital LLP Boosts Position in Zoetis Inc. (NYSE:ZTS)